Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure
Quince Therapeutics’ lead asset eDSP failed to meet the primary or secondary endpoints in the pivotal NEAT trial.
02 February 2026
02 February 2026
Quince Therapeutics’ lead asset eDSP failed to meet the primary or secondary endpoints in the pivotal NEAT trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.